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Abstract
Recent studies provided evidence that evaluation of thrombin generation identifies patients at thrombotic risk. Thrombin
generation has a central role in hemorrhage control and vascular occlusion and its measurement provides new metrics of
these processes providing sufficient evaluation of an individual’s hemostatic competence and response to anticoagulant
therapy. The objective of the study is to assess a new measure of hypercoagulability that predisposes to venous
thromboembolism in the postoperative period after radical prostatectomy. Pre- (day-1) and postoperative (hour 1, day 6,
month 1 and 10) blood samples of 24 patients were tested for plasma thrombin generation (peak thrombin), routine
hematology and hemostasis. Patients received low molecular weight heparin for thromboprophylaxis. Peak thrombin levels
were higher in patients compared to controls at baseline (p,0.001), and elevated further in the early postoperative period
(p,0.001). Longer general anesthesia and high body mass index were associated with increased thrombin generation after
surgery (p = 0.024 and p= 0.040). D dimer and fibrinogen levels were higher after radical prostatectomy (p = 0.001 and
p,0.001). Conventional clotting tests remained within the reference range. Our study contributed to the cognition of the
hypercoagulable state in cancer patients undergoing pelvic surgery and revealed the course of thrombin generation after
radical prostatectomy. Whilst it is unsurprising that thrombin generation increases after tissue trauma, further evaluation of
this condition during the postoperative period would lead urologists to an international and well-supported consensus
regarding thromboprophylaxis in order to provide better clinical outcome. Considering the routine evaluation of
procoagulant activity and extending prophylactic anticoagulant therapy accordingly may potentially prevent late
thrombotic events.
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Introduction
Worldwide 52% of hospitalized patients are judged to be at risk
of thrombotic events including deep venous thrombosis (DVT) or
pulmonary embolism (PE), which were adjudicated as the most
common cause of death after pelvic cancer surgery –like radical
prostatectomy (RP)– according to a prospective observational
study [1]. Most contemporary RP series report rates of thrombo-
embolic complications ranging from 0.8% to 6.2% (with the use of
various prophylactic measures), so there is no doubt that RP
carries a significant risk of potentially fatal venous thromboembo-
lism (VTE) [2]. Guidelines were composed to prevent thrombotic
events, but the risk assessment and prophylaxis after radical
prostatectomy is still under debate [3], [4].
Hypercoagulability identifies the imbalance of the coagulation
cascade toward the procoagulant condition due to an excessive
activation of coagulation enzymes without clinical signs of
thrombosis. Coagulation tests are used to screen for the presence
of hemostasis disorders and to monitor treatment. Hypercoagu-
lability is frequently associated with changes in prothrombin time
(PT), activated partial thromboplastin time (APTT), thrombin
time (TT) and fibrinogen (FNG) levels. D dimer is another well-
defined test to indicate hypercoagulation and hyperfibrinolysis.
Although the specificity of D dimer for DVT or PE is poor,
because of fibrin produced in cancer, inflammation, infection and
necrosis too, it is still a widely used initial test [5].
Recent trials measuring thrombin generation by fluorescent
substrate assay proved that this is a suitable method for estimating
the risk of thrombotic events under appropriate sample handling
and laboratory conditions [6], [7], [8], [9]. Elevated basal peak
thrombin generation was associated with a 74% increased risk of
VTE published in prospective LITE data [10]. This method
measures the amount of thrombin formed upon recalcification of
citrated plasma and by initiation of the cascade reaction by adding
exogenous activators like human recombinant tissue factor (TF)
and phospholipids [8].
In the present study, we assessed the extent of hypercoagula-
bility by measuring the plasma thrombin generation capacity in
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the early and late postoperative period after radical prostatectomy,
using commercially available kit. To the best of our knowledge,
this study is the first to evaluate the course of the hypercoagula-
bility in cancer patients undergoing major pelvic surgery.
Materials and Methods
In our prospective study, 24 patients with histology proven
localized prostate cancer were selected (mean age 61, range 50–70
years), and followed up after laparoscopic radical prostatectomy.
Patients with any anticoagulant medication or any medical
condition potentially affecting coagulation assessment, such as
severe chronic cardiovascular disease, advanced hepatic or renal
failure, previous thrombotic events and any other kind of
malignancy or previous treatment of prostate cancer were
excluded from the study. For comparison 20 male age matched
controls (mean age 60, range 42–76 years) without prostate cancer
and with the same exclusion criteria as for the patients were
recruited at the urology outpatient service. The prostate cancer
was excluded by the following inclusion criteria: total Prostate
Specific Antigen (tPSA) level ,1.5 ng/ml, digital examination of
prostate negative. The controls didn’t undergo any surgical
intervention, they were healthy volunteers of the age of the study
group or men seeking for treatment of mild dysuria. Written
informed consent was obtained from each participant. The local
ethics committee of the University of Debrecen (Debrecen,
Hungary) approved the study protocol.
Low molecular weight heparin (LMWH) administration (40 mg
or 4000 IU anti-Xa/day) was started one day prior to the surgical
intervention and was continued for 5 weeks after the laparoscopic
procedure according to the guidelines of the American Urological
Association (AUA) [4]. Patients were mobilized on the first
postoperative day.
Blood was collected from the antecubital vein into the
appropriate Vacutainer tubes (Beckton-Dickinson, NJ USA) 1
day prior, at 1 hour, 6 days, 1 and 10 months after radical
prostatectomy. Sampling was performed at least 12 hours after
LMWH administration to obtain heparin free plasma from
patients under therapy. PT, APTT, TT, FNG by Clauss method
and d dimer were determined by an automated coagulometer
(BCS-XP, Siemens, Germany) using Innovin, Pathromtin SL
(Siemens, Germany), Thrombin time and Fibrinogen reagent,
(Labexpert Ltd, Debrecen, Hungary), and Innovance d dimer
(Siemens, Germany), respectively. Measurement of antithrombin
(AT) activity (Innovance AT, Siemens, Germany) and LMWH
levels (Berichrom Heparin, Siemens) was performed by using
factor Xa and its chromogenic substrate. Hematology parameters
such as red blood cell (RBC), white blood cell (WBC) and platelet
count (PLT) were measured using a XE-2100D hematology
analyzer (Sysmex, Japan). PSA level from serum was determined
on Modular Analytics E170 using Total PSA Reagent (Roche
Diagnostics, Germany).
For the thrombin generation assay (TGA) citrated blood
samples were centrifuged at 20uC for 15 minutes at 3200 g within
one hour of venipuncture. Plasma was separated into a new tube
and centrifuged again (3200 g, 10 min), aliquots of the superna-
tant were stored at 270uC. Analysis was performed within three
weeks. Individual aliquots were defrosted in a 37uC water bath by
tilting for 15 minutes, vortex mixed for 5 seconds and sampled
immediately into black 96 well plates (Greiner GmbH, Germany).
TGA were carried out using TechnothrombinH TGA kit with
fluorescent substrate (1 mM containing 15 mM CaCl2) and
reagent C (low concentration of phospholipid micelles and
50 pM recombinant human tissue factor), according to the
manufacturer’s instructions. Reagent C was diluted tenfold in
the reaction. The reagents and the reader with plate were
preheated to 37uC. The enzyme reaction was detected with a
BIOTEK Flx800 reader. Results were evaluated with KC4 TGA
software. All the TGA kit, the Reader and the software were
purchased from Technoclone GmbH, Austria.
For statistical analysis the patients were divided into subgroups
according to the followings: tumour stage (PT2, n= 19; PT3,
n = 5) additional lymphadectomy (n= 12); narcosis time
($230 min, n= 12 and $230 min, n= 12); body mass index
(BMI, #25, n= 8 and $25, n= 14). Preoperative data were
compared to controls and the results of the postoperative samples
were compared to the preoperative ones (day-1). Statistical tests
were performed using GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego CA, www.graphpad.com). P
values were calculated according to the distribution of the given
data series, to the results of D’Agostino-Pearson and Shapiro-Wilk
normality tests and the option of paring: i.e. ‘‘preoperative results’’
to the ‘‘results of the controls’’ with unpaired t test (with Welch’s
correction or Mann Whitney test); ‘‘postoperative results’’ to the
‘‘preoperative results’’ with paired t test (and Wilcoxon signed rank
test). According to the Gaussian distribution we used Pearson or
Spearman test during correlation analysis in relation to FNG
levels, conventional clotting times and TGA parameters. P,0.05
is considered to indicate statistical significance.
Results
Based on the preoperative PSA values (mean: 8 ng/mL) and
histology of the prostate biopsy specimens, radical prostatectomy
was combined with regional lymphadenectomy in 12 out of 24
cases. The mean narcosis time was 233 minutes (range 140–335).
Mean blood loss was 314 mL (range 50–700) which correlates with
the changes in the RBC levels. No severe intra- or postoperative
complications occurred.
Histological examinations revealed prostate cancer in stages
between pT2a and pT3b in one case with a single lymph node
metastasis (Gleason Score 5–9). The median value of PSA was
reduced to the limit of detection. Salvage irradiation therapy and 6
month hormone therapy was given to 2 patients from the 6th
postoperative week. No relapse of malignancy was experienced in
any patient in the first ten postoperative months. Eighty-three
percent (20/24) of the study population was continent, and 42%
(10/24) of the patients had erection with or without medication.
No thrombotic complications occurred during the observational
period.
Detailed follow-up laboratory results of the 24 patients are
summarized in Table 1 and Table 2.
White blood cell counts were elevated one-hour postoperatively
and normalized afterwards. Platelet counts were the highest on the
sixth postoperative day and lowered afterwards. Prothrombin time
and TT were prolonged in the one-hour postoperative samples
and then returned back to the preoperative value. Activated partial
thromboplastin time was prolonged preoperatively compared to
the controls and shortened after the operation. Conventional
clotting tests remained in the reference range after surgical
procedure. Reference ranges in our laboratory are: PT: 7.5–12.8,
APTT: 26.5–37.7 and TT: 15.4–23.4 [sec]. Fibrinogen levels
decreased first, then doubled and decreased almost to the
preoperative value at one month. D dimer level was high at
one-hour postoperatively, further elevated by the sixth day and
normalized afterwards.
Thrombin generation measured by TGA was evaluated by the
peak thrombin concentration (nM), the area under the curve
Thrombin Generation after Prostatectomy
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(AUC), the lag phase, the peak time and the velocity index (V-
index; Table 2. and Figure). The reaction was triggered by 5 pM
tissue factor in all the measurements. Compared to the controls,
peak thrombin and AUC were elevated in the patients’
preoperative samples, while the other parameters of the thrombin
generation remained unchanged. The peak thrombin levels were
further elevated in the early postoperative period, reaching a
maximum by the sixth day, as did AUC, and normalized by the
end of the first month. Significant differences in the lag phase,
peak time and velocity index were seen in the postoperative one-
hour samples. None of the TGA parameters correlated with the
changes in fibrinogen levels except AUC on the sixth day
(p = 0.0038, Pearson correlation). No correlation between con-
ventional clotting times and changes in the thrombin generation
parameters were found, except for PT and TT on the sixth day,
where the correlation with the lag phase was significant.
Decreased antithrombin (AT) levels may increase the thrombin
generation thus we assessed its changes in the study samples.
Compared to the baseline, AT-levels were reduced one hour
postoperatively, which however was not significant. As patients
had been under prophylactic LMWH treatment and the presence
of LMWH in plasma is expected to decrease peak thrombin level
and AUC, the inhibitory effect of LMWH on FXa (aFXa activitiy)
in the plasma samples was measured and found to be below the
limit of detection in each of the samples (Table 2.).
The patients’ data was analyzed retrospectively for correlation
between different clinical parameters and peak thrombin levels.
Neither pathological tumor stage (pT) nor additional lymphade-
nectomy did alter TGA results significantly. Longer narcosis
resulted in increased peak thrombin levels in the first postoperative
sample (p = 0.024, unpaired t test with Welch’s correction).
Baseline plasma peak thrombin levels of patients with elevated
Table 1. Routine test results of patients before and following radical prostatectomy.
Parameter
Reference Range or
Mean±2SD of
Controls
Preoperative
sample1 Hour 1 Day 6 Month 1 Month 10
After Surgery1
tPSA * ,4.4 8.1 8.5 1.5 0.0 0.0
[ng/mL] 6.2–11.5 6.6–14.1 1.0–2.2 0.00–0.05 0.00–0.03
RBC 4.2–5.22 4.7 4.4 4.3 4.5 4.6
[T/L] 4.5–5.0 4.0–4.6 3.9–4.7 4.2–5.0 4.5–4.8
p,0.0001 p = 0.0001 p= 0.0013 NS
WBC 4.5–10.82 7.2 13.5 7.2 6.0 6.4
[G/L] 6.0–7.8 11.1–16.7 5.9–8.6 4.9–6.9 5.8–7.4
p,0.0001 NS p= 0.0203 NS
PLT 150–4002 203 199 244 237 228
[G/L] 173–231 156–261 213–293 185–298 176–266
NS p,0.0001 NS NS
PT 8.0 8.1 8.7 7.6 8.1 7.9
[sec] 7.4–8.73 7.8–8.3 8.2–9.0 7.4–8.0 7.8–8.3 7.7–8.0
p = 0.0007 p = 0.0002 NS NS
APTT 28.1 29.3 27.2 27.1 27.8 28.0
[sec] 26.7–29.53 27.6–30.7 25.4–29.2 26.2–30.8 26.0–30.7 26.8–30.7
NS NS p= 0.0157 NS
TT 17.3 17.9 18.5 16.7 17.9 18.9
[sec] 14.5–20.23 17.0–18.5 17.8–19.5 15.8–17.6 16.9–19.0 17.9–19.1
p = 0.0035 p = 0.0007 NS NS
Fng 1.5–4.02 3.3 2.8 5.3 3.7 3.1
[g/L] 2.8–4.0 2.5–3.2 4.9–5.7 3.4–4.2 2.9–3. 5
P = 0.0302 p,0.0001 0.0204
D dimer ,0.52 0.27 0.88 1.16 0.42 0.24
[mg Feu/L] 0.24–0.47 0.53–1.46 0.86–1.32 0.21–0.91 0.20–0.45
p = 0.0010 p = 0.0010 NS
1Results are given as mean and6SD or median and 25–75 percentile values, depending on the normality of the test results. P values are also calculated according to the
distribution of the given data series and the option of paring: i.e. ‘‘preoperative results’’ to the ‘‘results of the controls’’ with unpaired t test (with Welch’s correction or
Mann Whitney test); ‘‘postoperation results’’ to the ‘‘preoperative results’’ with Paired t test (and Wilcoxon signed rank test). Preoperative data were compared to
controls and the results of the postoperative samples were compared to the preoperative ones (day-1).
2reference range of the method applied.
3mean62SD of pooled control samples (n = 20) in the period of the study.
4ND=not determined.
Bold letters indicate significant differences.
doi:10.1371/journal.pone.0051299.t001
Thrombin Generation after Prostatectomy
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e51299
body mass index (BMI.25) were similar to the normal BMI
patients, however a significant difference was found on the sixth
postoperative day (p= 0.011, Mann Whitney test).
Discussion
The aim of the present study was to evaluate the changes in
hypercoagulable state after radical prostatectomy using thrombin
generation assay. This measurement provides new metrics of
hemorrhage control and vascular occlusion, and allows sufficient
evaluation of an individual’s hemostatic competence and response
to anticoagulant therapy [11], [12].
The results of our thrombin generation tests showed remarkable
changes following radical prostatectomy. An even more significant
difference in thrombin generation was found between the
preoperative patient group and healthy control group. When
compared to the controls, baseline thrombin generation and AUC
were higher in the cancer patients which finding could be due to a
variety of causes such as the presence of tumor cells, of
microparticles and tissue factor [13]. Tissue factor and micropar-
ticles highly enhance procoagulant activity and thus influence the
thrombin generation parameters [14], [15]. The difference of the
TGA parameters between the controls and the preoperative values
of the study population revealed increased procoagulant activity,
which were further stimulated by the surgical intervention. The
effect of the operation disappeared to the end of the first
postoperative month. This supports the findings of other studies
that the high-risk period after radical pelvic surgery ends before
the first month [3]. The difference compared to the control group
disappeared only by the 10 month check. The elevated baseline
TG levels indicate the possible malignant procogulant activity of
the prostate cancer, which is amplified by the surgical interven-
tion.
Butenas et al confirmed that prothrombin and AT levels are
dominant factors that influence thrombin generation when a
synthetic ‘‘plasma’’ system was supplemented with factors II, X,
XI, IX, VII, VIII and V, proteins C and S, AT and tissue factor
pathway inhibitor [16]. A 50% decrease of AT increased thrombin
production from 104% to 196%. However, as the decrease of AT
in our samples was less than 10% and all levels remained within
the reference range (80–120%), this cannot explain the remarkable
increase in the thrombin generation seen in our study.
Changes in white blood cell counts reveal the acute immuno-
logical reaction to the tissue trauma, with an early compensation.
Platelet count and conventional clotting tests varied somewhat, but
all remained within the reference ranges, similar to what was
observed after transurethral resection of benign prostatic hyper-
plasia [17]. Possible LMWH inhibitory actions on procoagulant
factors can be excluded as at the moment of blood sampling, the
levels in all samples were below the detection limit when
measuring inhibition of FXa, consequently LMWH could not
have influenced the result by decreasing procoagulant activity.
According to the correlation analysis of the FNG levels,
conventional clotting times and TGA parameters we found that
increased procoagulant activity is more readily detected when
using the TGA, than by measuring changes in PT, APTT and TT
levels. Elevated basic d dimer level was similar to published results
[18], [19]. Fibrinogen-levels did show a slower response to tissue
trauma, than d dimer and peak thrombin. Since we did not find a
correlation between fibrinogen and peak thrombin generation,
although fibrinogen influences thrombin generation [16], we
conclude that in this altered balance of hemostasis as seen in the
Table 2. Specific test results of patients before and following radical prostatectomy.
Parameter
Values of the
Control Group
Preoperative
sample1 Hour 1 Day 6 Month 1 Month 10
After Surgery1
Peak 206 302 330 420 289 244
thrombin 629 668 691 685 671 644
[nM] p = 0.0001 p= 0.0089 p,0.0001 NS NS
AUC 2841 3522 3513 4108 3638 3051
[nM*min] 6375 6505 6618 6468 6574 6444
p,0.0001 NS p,0.0001 NS p= 0.0209
lag phase 11.8 11.6 10.5 12.1 11.6 11.3
[min] 61.80 62.21 62.42 62.96 62.61 61.60
NS p,0.0001 NS NS NS
Peak time 16.9 16.6 14.3 16.0 16.1 16.0
[min] 61.92 62.52 63.45 63.61 62.99 61.46
NS p= 0.0004 NS NS NS
LMWH 0.12 NT3 0.03 0.07 0.06 NT3
[IU/mL] 0.02–0.06 0.03–0.09 0.02–0.09
AT 103 106 89 101 102 101
[%] 92–115 97–117 74–102 95–112 93–107 94–130
1Results are given as mean and6SD or median and 25–75 percentile values, depending on the normality of the test results. P values are also calculated according to the
distribution of the given data series and the option of pairing. Preoperative data were compared to controls and the results of the postoperative samples were
compared to the preoperative ones (day-1).
2limit of detection.
3No LMWH therapy.
Bold letters indicate significant differences.
doi:10.1371/journal.pone.0051299.t002
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patients, it has a lesser contributing effect to the rise in peak
thrombin levels or other TGA parameters.
Patients’ data were further analyzed for correlation between
different clinical parameters and peak thrombin levels. Patholog-
ical tumor stage (pT) or additional lymphadenectomy was not
significantly linked to TGA results. However, longer narcosis was
observed to correlate with increased peak thrombin levels in the
first postoperative sample. Baseline peak thrombin levels in plasma
of patients with elevated body mass index (BMI.25) were similar
to the normal BMI patients, but here a significant difference was
seen on the sixth postoperative day. Beijers et al investigated the
association between body composition and thrombin generation in
plasma of 586 individuals and found an association with higher
levels of thrombin generation in elderly women but not in men
[20]. We hypothesise that body shape (characterized by BMI) may
have a latent effect on procoagulant activity as BMI level caused
difference only on the 6th postoperative day but this statement
needs further evaluation.
Limitations of our study are (i) the relatively low number of
cases with as a consequence that the probability of having clinical
signs of thrombotic events during the follow-up was limited; (ii) two
of the patients were administered irradiation and hormone therapy
fro the 6th postoperative week; (iii) not all the data series showed
Gaussian distribution, which decreased the statistical power; and
(iv) there are other specific laboratory tests evaluating procoagu-
lant activity, which were not evaluated in our study.
In conclusion, our study contributed to the knowledge of the
pathophysiology of the hypercoagulable state of prostate cancer
patients undergoing major pelvic surgery. Recent studies provided
evidence that measurement of thrombin generation identifies
patients at risk of venous thromboembolism [10], [6], It’s well
known fact that surgical therapy of pelvic malignancies mean an
additional risk of venous thromboembolism due to the nature of
the intervention and the disease, but the stage of hypercoagula-
bility during the postoperative period of radical prostatectomy has
not been demonstrated yet. The goal of our present study was to
evaluate this level with the use of a test which usefulness was
proven by other studies. Although our case number was low to
reach statistical probability for clinical thrombotic events, our
results and recent articles present the power of thrombin
generation test to detect such a high increase of the hypercoag-
Figure 1. Thrombin generation parameters: Whiskers: 5–95 percentile graphs of peak thrombin (A), area under the curve (B), lag
time (C) and peak time (D). Labels of significance: *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0051299.g001
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ulability, which indicate the risk of thrombotic events as shown in
large studies [10].
Factors influencing thrombotic risk are still not well defined but
our results suggest that increased narcosis and BMI may
contribute to procoagulant activity in the postoperative period,
but this statement needs further assessment.
Our study together with recently published papers assessing risk
factors for arterial or venous thromboembolism suggests the need
for individual anticoagulant and antiplatelet management plan
likely to achieve a low incidence of thrombosis and prevent
bleeding. [21]. To reach this goal, multidisciplinary approach is
desirable.
Further evaluation of the hypercoagulable state in the postop-
erative period would lead urologists to an international and well
supported consensus where e.g. anticoagulant treatment is
considered for the first month only in order to provide a better
clinical outcome.
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